 "Pharma shares in focus; Aurobindo Pharma hits new high")
Shares of pharmaceutical companies were in focus and trading higher by up to 10% each on the Bombay Stock Exchange (BSE).
JB Chemicals & Pharmaceuticals (up 11% at Rs 252), Alembic Pharmaceuticals (5.5% at Rs 688), Aurobindo Pharma (3% at Rs 1,436), Ipca Laboratories (3% at Rs 698) and Dishman Pharmaceuticals (3% at Rs 158) were up 3%-10% each. Lupin, Sun Pharmaceutical Industries, Ajanta Pharma, Cadila Healthcare, Wockhardt and Unichem Laboratories were up 1%-2% each on the BSE.
At 1024 hours, S&P BSE Healthcare index, the largest gainer among sectoral indices, was up 1% or 162 points at 16,424, after hitting a high of 16,477 in intra-day trades. The S&P BSE Sensex was up 0.24% at 27,871.
Aurobindo Pharma was up 3% at Rs 1,432, after hitting a new high of Rs 1,444 in early morning trades on the BSE.
In the past seven trading sessions, the stock rallied 13% from Rs 1,277 on June 15, after the company received the final approval from the US Food & Drug Administration (US FDA) to manufacture and market extended Phenytoin sodium capsules, an anti-epileptic drug for controlling seizures.
On June 22, the company had received final approval from the USFDA to manufacture and market Entacapone tablets and Azithromycin injections.
Entacapone, a generic version of Comtan tablets of Orion Corporation, is used in the treatment of Parkingons's disease. Azithromycin is a generic version of Zitromax of Pfizer and is indicated for treatment of patients with infections including pneumonia.
JB Chemicals & Pharmaceuticals (up 11% at Rs 252), Alembic Pharmaceuticals (5.5% at Rs 688), Aurobindo Pharma (3% at Rs 1,436), Ipca Laboratories (3% at Rs 698) and Dishman Pharmaceuticals (3% at Rs 158) were up 3%-10% each. Lupin, Sun Pharmaceutical Industries, Ajanta Pharma, Cadila Healthcare, Wockhardt and Unichem Laboratories were up 1%-2% each on the BSE.
At 1024 hours, S&P BSE Healthcare index, the largest gainer among sectoral indices, was up 1% or 162 points at 16,424, after hitting a high of 16,477 in intra-day trades. The S&P BSE Sensex was up 0.24% at 27,871.
Aurobindo Pharma was up 3% at Rs 1,432, after hitting a new high of Rs 1,444 in early morning trades on the BSE.
In the past seven trading sessions, the stock rallied 13% from Rs 1,277 on June 15, after the company received the final approval from the US Food & Drug Administration (US FDA) to manufacture and market extended Phenytoin sodium capsules, an anti-epileptic drug for controlling seizures.
On June 22, the company had received final approval from the USFDA to manufacture and market Entacapone tablets and Azithromycin injections.
Entacapone, a generic version of Comtan tablets of Orion Corporation, is used in the treatment of Parkingons's disease. Azithromycin is a generic version of Zitromax of Pfizer and is indicated for treatment of patients with infections including pneumonia.